ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® (epinephrine nasal spray) Oral presentation to report results from real world data on the effectiveness of epinephrine nasal spray in clinical practice Case reports to detail real-world data and effective use of neffy in patients who experience anaphylaxis during oral food challenges or allergy immunotherapy SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Na ...

$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK- Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle- free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14 ...